Trimovate

Trimovate Cream is a combined topical preparation containing three active ingredients: clobetasone butyrate (a moderately potent corticosteroid), oxytetracycline (a tetracycline antibiotic), and nystatin (an antifungal agent).

It is prescribed for the short-term treatment of inflammatory skin conditions where bacterial or fungal secondary infection is present or likely.

Clobetasone butyrate reduces inflammation, redness, itching, and swelling by suppressing the local immune response in the skin.

Oxytetracycline provides broad-spectrum antibacterial activity against the bacteria commonly responsible for secondary skin infections.

Nystatin is effective against Candida species, the most common cause of cutaneous fungal infection.

The combination allows simultaneous treatment of the inflammatory component and any co-existing or anticipated microbial infection.

Trimovate is used in conditions such as infected eczema, infected insect bites, intertrigo (skin-fold inflammation), and other dermatoses where mixed bacterial and fungal infection is suspected.

It is intended for short-term use only, typically no longer than seven days, to control the acute inflammatory and infective phase.

Apply a thin layer of Trimovate Cream to the affected area of skin up to four times daily. Gently rub it in until absorbed.

Wash your hands before and after application unless you are treating the hands.

Do not cover the treated area with airtight or occlusive dressings unless directed by your doctor, as this increases steroid absorption.

Treatment should not normally exceed seven days. If the infection has not resolved or the condition worsens, return to your prescriber for reassessment.

Do not use Trimovate on the face for more than five days. Stop treatment once the inflammation and infection have settled.

Apply thinly to the affected area up to four times daily. The amount used should be the minimum necessary to cover the affected area. A fingertip unit (approximately 0.

5 g) covers an area of skin roughly the size of two adult palms. Treatment duration should not exceed seven days without medical review. No specific dose adjustment is applicable.

Use with caution in children, on large surface areas, and in skin-fold areas where absorption is higher.

Common local side effects include mild burning or stinging on application, skin irritation, and dryness. These usually resolve quickly.

Uncommon effects include allergic contact dermatitis to any of the three components, skin thinning with prolonged use, stretch marks (striae), visible blood vessels (telangiectasia), and folliculitis.

Prolonged or excessive use, particularly under occlusion or on the face, may lead to steroid-related skin changes including perioral dermatitis, acneiform eruptions, and depigmentation.

Significant systemic absorption is unlikely with short-term appropriate use. Resistance to oxytetracycline may develop with prolonged antibacterial use.

Sensitisation to topical antibiotics or nystatin is possible but uncommon.

Do not use Trimovate for longer than seven days without reassessment. Prolonged use of topical corticosteroids can cause skin thinning and make the skin more susceptible to infection.

Avoid the eyes and mucous membranes. If used on the face, limit treatment to five days.

In children, use the minimum amount for the shortest time, as their higher surface-area-to-body-weight ratio increases the risk of systemic absorption.

Do not use under occlusive dressings unless directed.

Trimovate is contraindicated in patients with known hypersensitivity to clobetasone butyrate, oxytetracycline, nystatin, or any excipient.

It must not be used on viral skin infections (herpes simplex, chickenpox, shingles), primary bacterial skin infections without appropriate systemic therapy, tuberculosis of the skin, acne vulgaris, rosacea, or perioral dermatitis.

It is not suitable for use on leg ulcers.